These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25829274)

  • 21. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
    Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
    Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives for immunotherapy in glioblastoma treatment.
    Finocchiaro G; Pellegatta S
    Curr Opin Oncol; 2014 Nov; 26(6):608-14. PubMed ID: 25210870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
    Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
    Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
    Samaha H; El Naggar S; Ahmed N
    Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
    [No Abstract]   [Full Text] [Related]  

  • 25. [Immunotherapy for malignant glioblastoma].
    Nose T; Nakagawa K
    No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
    [No Abstract]   [Full Text] [Related]  

  • 26. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
    Sengupta S; Mao G; Gokaslan ZS; Sampath P
    Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR targeted inhibition resistance: compensatory activation of ERBB family members in glioblastoma cancer stem-like cells promotes proliferation.
    Gursel DB; Schlaff CD; Boockvar JA
    Neurosurgery; 2012 Oct; 71(4):N17-8. PubMed ID: 22989968
    [No Abstract]   [Full Text] [Related]  

  • 28. The intersection between genetic engineering and immunotherapy: taking a BiTE out of glioblastoma.
    Njoku I; Boockvar JA
    Neurosurgery; 2013 Jun; 72(6):N16-7. PubMed ID: 23685511
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solving the riddle of glioblastoma: The hope for immunotherapy.
    Bashir R; Mohile NA
    Neurology; 2016 Jun; 86(24):2220-1. PubMed ID: 27225224
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of human glioblastoma by specific immunotherapy.
    Wood GW; Holladay FP; Oweity T; Watanabe I
    Kans Med; 1993 Jul; 94(7):200-2, 206. PubMed ID: 8230943
    [No Abstract]   [Full Text] [Related]  

  • 32. EGFRvIII--a stable target for anti-EGFRvIII therapy.
    Banaszczyk M; Stoczynska-Fidelus E; Winiecka-Klimek M; Bienkowski M; Och W; Rieske P; Piaskowski S
    Anticancer Res; 2013 Dec; 33(12):5343-8. PubMed ID: 24324068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for glioblastoma: the devil is in the details.
    Lesniak MS
    J Clin Oncol; 2011 Aug; 29(22):3105; author reply 3105-6. PubMed ID: 21709193
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy in glioblastoma: emerging options in precision medicine.
    Hodges TR; Ferguson SD; Heimberger AB
    CNS Oncol; 2016 Jul; 5(3):175-86. PubMed ID: 27225028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy.
    Buchroithner J; Pichler J; Marosi C; Widhalm G; Seiz-Rosenhagen M; Novosielski M; Oberndorfer S; Ruckser R; Rössler K; Azizi A; von Campe G; Bordihn K; Felzmann T
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):76-7. PubMed ID: 24321210
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
    Yong RL; Lonser RR
    World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
    [No Abstract]   [Full Text] [Related]  

  • 38. Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99.
    Kim YH; Tran TA; Lee HJ; Jung SI; Lee JJ; Jang WY; Moon KS; Kim IY; Jung S; Jung TY
    Oncotarget; 2016 Aug; 7(31):50535-50547. PubMed ID: 27409668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.